Windley Rodney D sold $2.1M of AVAH

Windley Rodney D sold 180,000 shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $11.50 ($2.07M total) on 2026-08-20.

Original reporting
SEC EDGAR · Windley Rodney D
Published Aug 24, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVAH
Bearish
medium confidence
Mentioned
$AVAH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVAHBearishLow
01

Why it matters

The disclosed sale adds new information about insider holdings, modestly affecting AVAH's perceived insider confidence.

02

Market read

Primary insider sale filing; modest relevance for short‑term traders.

03

What to watch

No disclosed reason for the sale; could be tax planning or diversification.

Relevance 6/10Novelty 6/10Timing: filed today

Background

Form 4 filings disclose insider transactions; director sales are monitored by investors for potential signals.

Company-level read

Ticker impact

$AVAHBearishMedium confidence
Context

Director Rodney D. Windley sold 180,000 shares for $2.07M in a Form 4 filing.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $2M sale by a director is material for a mid‑cap healthcare company, but the amount is not large enough to trigger a sharp move.

Market effects

May prompt scrutiny of Aveanna's governance but limited sector impact.

US healthcare sector sees minimal ripple.

None

Counterpoint

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Aveanna Healthcare Holdings, Inc.

    US‑listed healthcare services provider (ticker AVAH).

  • Rodney D. Windley

    Director of Aveanna who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.